Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    ARIA Associated with Aducanumab

    ARIA Associated with Aducanumab

    FromNeurology Minute

    Start listeningView podcast show

    ARIA Associated with Aducanumab

    FromNeurology Minute

    ratings:
    Length:
    3 minutes
    Released:
    Mar 23, 2022
    Format:
    Podcast episode

    Description

    Dr. Lon Schneider discusses the development of ARIA in Phase 3 EMERGE and ENGAGE trials that led to the FDA's accelerated approval of aducanumab for the treatment of MCI Alzheimer's disease. Show references: https://www.alzforum.org/news/research-news/aduhelm-phase-3-data-aria-common-sometimes-serious
    Released:
    Mar 23, 2022
    Format:
    Podcast episode

    Titles in the series (100)

    The Neurology Minute podcast delivers a brief daily summary of what you need to know in the field of neurology, the latest science focused on the brain, and timely topics explored by leading neurologists and neuroscientists. From the American Academy of Neurology and hosted by Stacey Clardy, MD, PhD, FAAN, with contributions by experts from the Neurology journals, Neurology Today, Continuum, and more.